AIMEDBIO is a spin-off company from Samsung Medical Center (SMC) established in August 2018. AIMEDBIO aims to provide therapeutic solutions to patients with serious brain diseases, including neuro-oncological and -degenerative diseases, to save patients’ lives and improve patients’ quality of life. Based on solid global networks with key opinion leaders in the field, an excellent research team with profound achievements, and R&D pipelines with an outstanding drug development platform, AIMEDBIO is an emerging leader in innovative brain disease treatment.
AimedBio
Category:
Venture
Main Business Area
AIMEDBIO specializes in the clinical development of brain diseases. AIMEDBIO uses its brain-oriented multi-disciplinary platform, consisting of largely five parts – big data, antibody-drug conjugate, blood-brain barrier penetration, brain immune modulation and patient-derived model (PDC/PDX), along the development process of therapeutics for brain diseases.
| Contact Details | 11F MK TOWER, 67 JEONGUI-RO, SONGPA-GU, SEOUL (+82) 2-6285-0743aimedbio@aimedbio.com |
|---|
Find out more companies
Related products
-
VentureMedigen Human Care
T cell immunotherapies for solid tumors, vaccine safety and natural immunity
-
-
-
-
Venture
K-Cell Co., Ltd.